A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... a 20.2% reduction in weight at 72 weeks, compared to 13.7% with the maximum tolerated ...

In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative ... their brand names Ozempic and Zepbound, researchers have ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the effects weight-loss ... dose of Zepbound on March 7, 2024.

How Much Weight Can You Lose in ... in four weeks. That’s about one and a half pounds a week. Tirzepatide is a once-weekly injection typically sold under the brand names Zepbound and Monjouro.

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

Patients achieved an estimated weight loss of 9.7% on ... after 36 weeks or whether the trends suggest further improvements are possible in longer trials. In a study of Eli Lilly’s Zepbound ...

Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management. Klarity connects you with healthcare ...